In contrast, in the HER2-positive tumour group, the Elston and Ellis grade was higher than in HER2-negative and HER2-low tumours (P = 0.002 and 0.003), HR expression was less frequent (P < 0.001) and relapses occurred earlier (after 58.1 months versus 78.1 for HER2-negative and 72.2 for HER2-low tumours; P = 0.007 and 0.039, respectively). The gene discussed is ERBB2; the disease is neoplasm.